Safety and efficacy of jaktinib (a novelJAKinhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: Asingle‐arm,open‐label, phase 2, multicenter study
Authors:
Open Access
- 19 July 2023
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 98 (10) , 1579-1587
Abstract
Ruxolitinib has demonstrated efficacy in patients with myelofibrosis (MF). However, substantial number of patients may not respond after 3–6 months of treatment or develop resistance over time. In this phase 2 trial, patients with a current diagnosis of intermediate or high‐risk MF who either had an inadequate splenic response or spleen regrowth after ruxolitinib treatment were enrolled. All patients received jaktinib 100 mg Bid. The primary endpoint was the proportion of patients with ≥35% reduction in spleen volume (SVR 35) at week 24. The secondary endpoints included change of MF‐related symptoms, anemic response, and safety profile. From July 6, 2021, to January 24, 2022, 34 ruxolitinib‐refractory or relapsed patients were enrolled, 52.9% (18 of 34) were DIPSS intermediate 2 or high risk. SVR 35 at week 24 was 32.4% (11 of 34, 95% CI 19.1%–49.2%) in all patients and 33.3% (6 of 18, 95% CI 16.3%–56.3%) in the intermediate 2 or high‐risk group. A total of 50% (8 of 16) transfusion‐independent patients with hemoglobin (HGB) <100 g/L at baseline had HGB elevation ≥20 g/L within 24 weeks. Furthermore, 46.4% (13 of 28) of patients had a ≥ 50% decrease in the total symptom score (TSS 50) at week 24. The most common grade ≥3 treatment‐emergent adverse events (TEAEs) were thrombocytopenia (32.4%), anemia (32.4%), and leukocytosis (20.6%). In total, 13 (38.2%) of 34 patients had serious adverse events (SAE), of which drug‐related SAEs were found in 5 patients (14.7%). These results indicate that jaktinib can be a promising treatment option for patients with MF who have either become refractory to or relapsed after ruxolitinib treatment.Keywords
Funding Information
- National Natural Science Foundation of China (82100159)
This publication has 30 references indexed in Scilit:
- Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosisCancer, 2019
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With MyelofibrosisJAMA Oncology, 2018
- Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trialThe Lancet Haematology, 2018
- Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuationBlood, 2017
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trialJournal of Hematology & Oncology, 2017
- Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based StudyJournal of Clinical Oncology, 2015
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-IHaematologica, 2015
- Outcome Of Patients (pts) With Myelofibrosis (MF) After Ruxolutinib (Rux) TherapyBlood, 2013
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for MyelofibrosisNew England Journal of Medicine, 2012
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)Blood, 2010